The role of hsa-miR-21-5p, hsa-miR-210-3p, hsa-miR-197-3p, hsa-miR-125a-5p and hsa-miR-206-3p as circulating microRNA signatures in amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis, often called ALS, is a relentless disease that slowly dismantles the body's ability to move. It strikes the motor neurons, the specialized nerve cells that act as the brain's messengers to the muscles. When these cells die, the muscles they control waste away, leading to paralysis and, eventually, the inability to breathe. For decades, doctors have struggled to find a reliable way to diagnose the disease early or to track how quickly it is moving through a patient's body. The current methods rely heavily on clinical observation, which can be slow and imprecise. To solve this, scientists have turned their attention to the body's own chemical language, specifically looking for tiny fragments of genetic material called microRNAs. These are not the long strands of DNA that hold our master blueprint, but rather small, regulatory pieces that act like volume knobs, turning the activity of other genes up or down. Because these molecules are remarkably stable and can be found floating in the fluid that surrounds the brain and in the blood, researchers believe they might serve as a clear, measurable signal of what is happening inside the nervous system.

In a recent study, a team of researchers at the University of Thessaly in Greece set out to see if they could find such a signal in patients with ALS. They focused on five specific microRNAs that previous research suggested might be involved in the disease's complex biology, including processes like cellular stress, muscle repair, and inflammation. To test this, they gathered samples from 150 people: 50 patients who had just been diagnosed with ALS, 50 healthy individuals, and 50 patients who had other neurological conditions but not ALS. The team collected two types of samples from each person: blood serum and cerebrospinal fluid, the clear liquid that cushions the brain and spinal cord. Using a highly sensitive laboratory technique, they measured the amount of each of the five microRNAs in these samples to see if the levels differed between the sick and the healthy groups.

The results revealed a distinct molecular fingerprint for ALS. In both the blood and the spinal fluid of the patients, three of the microRNAs were found in much higher quantities than in the control groups. Specifically, the levels of hsa-miR-210-3p, hsa-miR-206-3p, and hsa-miR-21-5p were significantly elevated. At the same time, one microRNA, hsa-miR-125a-5p, was found in lower amounts. Another candidate, hsa-miR-197-3p, showed no clear difference between the groups, effectively acting as a control to show that the changes were specific to the disease. The researchers found that these changes were not just random noise; they were consistent enough to distinguish patients with ALS from healthy people with a high degree of accuracy. In fact, one of the elevated microRNAs, hsa-miR-210-3p, was so effective at telling the difference that it performed almost as well as a perfect diagnostic test.

Beyond simply identifying who had the disease, the study looked at whether these chemical levels could tell doctors how severe the illness was or how fast it was progressing. The team analyzed the data alongside clinical scores that measure a patient's ability to perform daily tasks. They discovered a strong link between the levels of hsa-miR-21-5p and the severity of the disease. As the levels of this microRNA went up, the patients' functional scores went down, indicating a more advanced stage of the disease. Furthermore, the levels of hsa-miR-206-3p and hsa-miR-210-3p were tied to how long the patients had been sick and how rapidly their condition was worsening. Patients whose disease progressed more quickly tended to have higher levels of these specific molecules. This suggests that these microRNAs are not just markers of the disease's presence, but also reflect its intensity and pace.

To understand what these changes actually meant for the body, the researchers used computer models to predict which genes these microRNAs were likely controlling. They then analyzed the biological pathways associated with those genes. The analysis pointed to a few key themes: the cells were under significant stress, their ability to repair damaged DNA was being challenged, and there was a strong signal of immune system activation. The data also highlighted issues with the structural integrity of nerve fibers and the remodeling of muscle tissue. This paints a picture of a body in a state of chronic crisis, where the nervous system is struggling to cope with damage while the immune system and muscle repair mechanisms are in overdrive. The study did not find a link between these specific microRNA levels and the type of ALS a patient had, such as whether it started in the limbs or the face, nor did it find a difference between fast and slow progressors based on a simple split of the group, suggesting the relationship is more about the continuous scale of the disease rather than distinct categories.

While the findings are promising, the researchers are careful to note that this was a single snapshot in time, taken when patients were first diagnosed. They cannot yet say for certain if these microRNA levels cause the disease or if they are simply a reaction to it. The study also relied on a specific set of five molecules, meaning there could be other important signals they missed. However, the consistency of the results across both blood and spinal fluid, and the clear connection to how sick the patients were, offers a compelling new direction. It suggests that a simple blood test or fluid analysis could one day provide doctors with a precise tool to diagnose ALS earlier and monitor its course more accurately, moving beyond guesswork to a clearer understanding of the disease's progression.